Research Analysts Set Expectations for BTAI Q1 Earnings

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) – HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for BioXcel Therapeutics in a note issued to investors on Thursday, April 2nd. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($0.48) for the quarter. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for BioXcel Therapeutics’ current full-year earnings is ($24.39) per share. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.52) EPS and FY2027 earnings at ($1.12) EPS.

BioXcel Therapeutics (NASDAQ:BTAI) last announced its quarterly earnings results on Friday, March 27th. The company reported ($0.58) EPS for the quarter, meeting the consensus estimate of ($0.58). The company had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.15 million.

Several other equities analysts also recently commented on BTAI. Zacks Research upgraded BioXcel Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, March 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioXcel Therapeutics in a research report on Wednesday, January 21st. Rodman & Renshaw started coverage on shares of BioXcel Therapeutics in a research report on Tuesday, March 17th. They set a “buy” rating and a $17.00 target price on the stock. Finally, Wall Street Zen lowered shares of BioXcel Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $11.00.

BioXcel Therapeutics Stock Down 4.8%

BTAI stock traded down $0.06 during midday trading on Tuesday, hitting $1.09. 786,554 shares of the company traded hands, compared to its average volume of 1,391,630. BioXcel Therapeutics has a twelve month low of $1.06 and a twelve month high of $8.08. The business has a 50 day simple moving average of $1.53 and a 200-day simple moving average of $1.88. The stock has a market capitalization of $29.38 million, a price-to-earnings ratio of -0.16 and a beta of 0.30.

Hedge Funds Weigh In On BioXcel Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Diversify Wealth Management LLC bought a new position in BioXcel Therapeutics during the second quarter worth $27,000. HRT Financial LP acquired a new stake in BioXcel Therapeutics during the fourth quarter worth $28,000. XTX Topco Ltd acquired a new stake in BioXcel Therapeutics during the second quarter worth $42,000. Goldman Sachs Group Inc. acquired a new stake in BioXcel Therapeutics during the first quarter worth $50,000. Finally, Geode Capital Management LLC boosted its stake in BioXcel Therapeutics by 27.7% during the second quarter. Geode Capital Management LLC now owns 28,182 shares of the company’s stock worth $51,000 after buying an additional 6,120 shares in the last quarter. Institutional investors own 30.68% of the company’s stock.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.